Clinical Trials on Metastatic Hormone Sensitive Prostate Cancer

Total 16939 results

Roswell Park Cancer Institute
Active Biotech AB

Completed

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

Prostate Cancer | Advanced Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Jonsson Comprehensive Cancer Center
Novartis; Stand Up To Cancer; Prostate Cancer Foundation

Active, not recruiting

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Peking Union Medical College Hospital

Recruiting

68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis

Prostate Cancer Metastatic

China
Rohan Garje
Janssen Scientific Affairs, LLC

Not yet recruiting

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (LUNAAR)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Praful Ravi, MB BCHir, MRCP
Eli Lilly and Company; Bayer

Active, not recruiting

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Non-metastatic Prostate Cancer

United States
British Columbia Cancer Agency

Recruiting

177Lu-HTK03170 in mCRPC With PSMA Positive Disease

Prostate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer

Canada
ORIC Pharmaceuticals

Recruiting

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Metastatic Prostate Cancer | Neuroendocrine Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma | Castration-Sensitive Prostate Carcinoma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Terminated

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Hormone-Resistant Prostate Cancer

United States
Tianjin Medical University Second Hospital

Recruiting

Selective Treatment According to Molecular Subtype of Prostate Cancer (STAMP)

Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

China
National Cancer Institute (NCI)

Active, not recruiting

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Castrate Sensitive Prostate Cancer

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (ASPIRE-PCa)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Spain, Taiwan, France, Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, Germany, Indonesia, Israel, Italy, Korea, Republic of, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Sin... and more
Providence Health & Services
MedImmune LLC

Completed

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Cancer of the Prostate

United States
Fudan University

Recruiting

Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Disease

China
Hongqian Guo
AstraZeneca; Nanjing Chia-tai Tianqing Pharmaceutical

Recruiting

The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation

Prostate Cancer | Metastatic Prostate Cancer | Prostate Carcinoma

China
Institute of Cancer Research, United Kingdom
Prostate Cancer UK

Recruiting

Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO (MAESTRO)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

United Kingdom
Astellas Pharma Global Development, Inc.
Pfizer

Completed

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) (TRUMPET)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

United States
Alliance Foundation Trials, LLC.
Bayer

Recruiting

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)

Prostate Cancer | Metastatic Prostate Cancer | Prostate Cancer Metastatic | Castrate Resistant Prostate Cancer

United States
Dana-Farber Cancer Institute
Novartis

Not yet recruiting

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
University of California, San Francisco
Conquer Cancer Foundation

Completed

MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Bayer; Janssen, LP; Prostate Cancer Clinical Trials Consortium

Completed

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

Stage IV Prostate Adenocarcinoma | Hormone-refractory Prostate Cancer | Prostate Carcinoma Metastatic to the Bone

United States
Sanofi
Genzyme, a Sanofi Company

Completed

E3-Hormone Refractory Prostrate Cancer Taxotere Combination

Prostate Cancer | Metastatic | Hormone Refractory

Brazil, South Africa, Sweden, Germany, Hungary
Vadim S Koshkin
Eli Lilly and Company; Prostate Cancer Foundation

Active, not recruiting

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer (UPLIFT)

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate Carcinoma

United States
Fundacao Champalimaud

Unknown

Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer

Metastatic Prostate Cancer | Prostate Adenocarcinoma

Portugal
Northwestern University
National Cancer Institute (NCI); AstraZeneca

Active, not recruiting

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Cancer Metastatic Castration-Resistant | Abnormal DNA Repair

United States
Northwestern University

Recruiting

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Refractory Prostate Cancer | Castration-Resistant Prostatic Cancer

United States
Peter MacCallum Cancer Centre, Australia
United States Department of Defense; Advanced Accelerator Applications; Australian... and other collaborators

Active, not recruiting

In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy (UpFrontPSMA)

Metastatic Hormone Naive Prostate Cancer

Australia
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Epizyme, Inc.; Pfizer

Active, not recruiting

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Epizyme, Inc.

Active, not recruiting

A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer (CELLO-1)

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Spain, Belgium
Amgen

Completed

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Cancer | Prostate Cancer | Castrate-Resistant Prostate Cancer | Mestastatic Prostate Cancer
Fudan University

Unknown

Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Metastatic

China
Canisius-Wilhelmina Hospital
ZonMw: The Netherlands Organisation for Health Research and Development

Recruiting

Dutch National Randomized Study: PSMA-PET/CT as a Triage Tool for Pelvic Lymph Node Dissection in Prostatectomy Patients (PSMA-SELECT)

Prostate Cancer | Prostate Cancer Metastatic | Lymph Node Metastases

Netherlands
Fudan University

Unknown

Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer

Prostate Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Bone Metastases | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Soft Tissue Metastases

United States
Arno Therapeutics

Unknown

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Metastatic Prostate Cancer | Androgen-independent Prostate Cancer

United Kingdom
Swiss Group for Clinical Cancer Research

Active, not recruiting

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Metastatic Breast Cancer | Bone Metastases | Metastatic Prostate Cancer

Switzerland, Germany, Austria
Xinhua Hospital, Shanghai Jiao Tong University...

Unknown

Evaluation of the Metastasis and Recurrence of Prostate Cancer

Prostate Cancer Recurrent | Prostate Cancer Metastatic | Prostate Cancer (Diagnosis) | Prostate Cancer Stage

China
Janssen Research & Development, LLC

Completed

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Metastatic Breast Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Belgium, Spain, Germany, Sweden, Australia, United Kingdom
British Columbia Cancer Agency

Completed

MSG Use With 18F-DCFPyL PET/CT Imaging

Prostate Cancer | Prostate Cancer Metastatic | Prostatic Neoplasm

Canada
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
AstraZeneca

Recruiting

The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation (PROspect)

Prostate Cancer | Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer

China
Abramson Cancer Center at Penn Medicine

Recruiting

FTT PET/CT in Metastatic Prostate Cancer

Prostate Cancer Metastatic

United States
St Vincent's Hospital, Sydney

Recruiting

Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction (PICASSO)

Metastatic Prostate Cancer

Australia
Sun Yat-sen University

Not yet recruiting

The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer

Metastatic Prostate Cancer

China
Massachusetts General Hospital
Pfizer; Prostate Cancer Foundation; Calithera Biosciences, Inc

Not yet recruiting

Telaglenastat + Talazoparib In Prostate Cancer

Prostate Cancer Metastatic

United States
Radboud University Medical Center
VGZ health insurance (NL); Paul Speth Foundation (NL); Radboud Oncology Fund...

Recruiting

imPlementing ROutine Molecular Characterization in Patients With Metastatic Castration Resistant ProstaTe Cancer by NGS (PROMPT)

Metastatic Prostate Cancer

Netherlands
Association Pour La Recherche des Thérapeutiques...

Completed

Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel (CABASTY)

Prostate Cancer Metastatic

France, Germany
Columbia University

Active, not recruiting

Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

Metastatic Prostate Cancer

United States
Chang Gung Memorial Hospital

Completed

The Role of Ga68-PSMA-11 PET Imaging in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

Metastatic Prostate Cancer

Taiwan
Eli Lilly and Company
Sarah Cannon Development Innovations

Completed

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

Prostate Cancer Metastatic

United States

Clinical Trials on Metastatic Hormone Sensitive Prostate Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations